Loading clinical trials...
Loading clinical trials...
This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.
Age
18 - 26 years
Sex
FEMALE
Healthy Volunteers
Yes
Univeristy of Michigan
Ann Arbor, Michigan, United States
Start Date
January 1, 2013
Primary Completion Date
April 1, 2014
Completion Date
April 1, 2014
Last Updated
July 22, 2015
661
ACTUAL participants
MeFirst Tailored Intervention
BEHAVIORAL
Lead Sponsor
University of Michigan
NCT06926062
NCT02624349
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions